, Genitourinary Medical Oncologist, MD Anderson Cancer Center, shared a post on X:
“ Check out our single-center, real-world experience with belzutifan in 22 patients with metastatic Clear Cell Renal Cell Carcinoma who were treated prior to the FDA approval. Led by our outstanding pharmacist, Emily Wang.
Belzutifan had meaningful activity in this heavily pre-treated cohort with ORR of 36.4%, median PFS of 8.5 months, and median OS of 14.7 months. We provide a detailed summary of the responders to belzutifan and our experience managing AEs of hypoxia and anemia.“
Source: Andy Hahn/X